Seraseq® ctDNA Prostate MixWhile early stage prostate cancer is often able to be surgically cured, castration resistant metastatic prostate cancer (mCRPC) is a difficult disease to manage with a 5 year survival rate of about 30%. Recent advances have shown that mCRPC can be managed with PARP inhibitor therapy if there are appropriate homologous recombination repair (HRR) gene mutation present in the tumor. LGC Clinical Diagnostics has produced the Seraseq ctDNA Prostate Mix to